RA Capital Management’s 71 Stock Portfolio List

Up to date on June thirteenth, 2022 by Nikolaos Sismanis

Based in 2002 by Peter Kolchinsky and Wealthy Aldrich, RA Capital Administration is a Boston-based hedge fund specializing in multistage life science investments. The fund holds round $10.1 billion in belongings below administration (AUM). The agency is comprised of execs with coaching in biology, chemistry, and drugs who possess business expertise on the government and board ranges.

Buyers following the corporate’s 13F filings during the last 3 years (from mid-Might 2019 by means of mid-Might 2022) would have generated annualized complete returns of -3.3%. For comparability, the S&P 500 ETF (SPY) generated annualized complete returns of 16.1% over the identical time interval.

Word: 13F submitting efficiency is completely different than fund efficiency. See how we calculate 13F submitting efficiency right here.

You possibly can obtain an Excel spreadsheet with metrics that matter of RA Capital Administration’s present 13F fairness holdings beneath:

Hold studying this text to be taught extra about RA Capital Administration.

Desk Of Contents

RA Capital Administration’s Technique & Values

RA Capital is a novel hedge fund, as 100% of its portfolio investments are allotted within the healthcare sector. The corporate holds years of expertise within the business. It’s devoted to evidence-based investing in listed and non-listed life science corporations within the varied phases of growing medicine, medical gadgets, and diagnostics.

Its technique consists of offering seed capital to startups, main non-public funding rounds, and staying by an organization’s aspect by means of its journey in the direction of an IPO. RA Capital’s distinctive perception into the sector permits corporations to take their early concepts from the labs to a commercialized product.

What differentiates Kolchinsky and his crew from different hedge funds is their experience in RNA, protein-folding correctors, and gene remedy. Such experience is uncommon, and that is doubly true when that data is mixed with finance and investing experience.

With most funds specializing in extra typical funding concepts, very often mimicking the foremost indices, Ra Capital presents its purchasers another funding technique that makes an attempt to bypass the general market’s systematic threat and returns.

The agency’s values stand on being aware of the methods during which RA interacts with each its personal individuals and people exterior the corporate. Mr. Kolchinsky has developed a set of ideas for RA, by which working relationships are based on belief, collaboration, diligence, and integrity. Mr. Kolchinsky believes that is how everybody’s potential is maximized and robust relationships are constructed.

Portfolio Developments & Non-public Investments

Because the fund helps information small corporations when they’re getting began and hopes to realize an IPO, RA Capital holds each private and non-private corporations. The general public equities a part of the fund at the moment has 71 shares, the highest 10 of which account for practically 56.6% of the whole weight.

The corporate’s technique is mirrored in these holdings, as most of them are straight out of their IPO section, with very brief buying and selling histories and a mean market capitalization of round $1.06 billion. As talked about, 100% of the holdings are within the life sciences sector.

Supply: 13F filings, creator

In the course of the previous quarter, RA Capital made the next noteworthy portfolio adjustments:

New Buys:

• Biogen Inc (BIIB)
• Veru Inc (VERU)
• PepGen Inc (PEPG)
• NanoString Applied sciences Inc (NSTG)
• Enanta Prescribed drugs Inc (ENTA)
• AN2 Therapeutics Inc (ANTX)
• Natera Inc (NTRA)
• Vera Therapeutics Inc (VERA)
• Guardant Well being Inc (GH)
• ChemoCentryx, Inc. (CCXI)

New Sells:

• Syros Prescribed drugs Inc (SYRS)
• Cogent Biosciences Inc (COGT)
• C4 Therapeutics, Inc. (CCCC)
• Silverback Therapeutics, Inc. (SBTX)
• Ikena Oncology Inc (IKNA)
• Nautilus Biotechnology Inc (NAUT)
• Adagio Therapeutics Inc (ADGI)

Most of the fund’s holdings, nevertheless, should not listed and consist of personal funding of their early phases, earlier than commercialization. Out of RA Capital’s 288 non-public investments, roughly 140 have resulted in a profitable exit, which is a testomony to administration’s expertise in figuring out diamonds within the tough and nurturing them.

Among the firm’s non-public highlights embody the next investments:

Novavax, Inc. (NVAX)

Regardless of being a publicly listed firm, RA Capital entered right into a $200 million non-public funding spherical earlier in June, as Novavax was in want of capital. RA Capital’s experience and value-creation within the sector shortly materialized, as shares have greater than tripled since.

Moderna, Inc. (MRNA)

Moderna has been occupying the investing headlines over the previous few months, as a result of rollout of its COVID-19 vaccine. The corporate has been publicly listed for practically two years, during which interval shares have rewarded buyers with multi-bagger returns. RA Capital invested within the firm again in 2015, at a fraction of its present valuation.

Pandion Therapeutics Holdco LLC (PAND)

Lastly, the fund participated in Pandion’s Collection B spherical of $80 million. The biotech firm went public simply months after, at a valuation practically six occasions increased than its non-public funding. Contemplating that the corporate is lacking from RA Capital’s newest 13F holdings, the hedge fund booked a fast multi-bagger revenue in a matter of months.

These are only a glimpse of RA Capital’s a number of successes in the case of its non-public allocation of funds.

Ultimate Ideas

RA Capital Administration is a particular hedge fund. Whereas the fund’s public-equity returns could seem depressed, its precise returns ought to be a lot increased, derived from investing in healthcare corporations earlier than they go public. Mr. Kolchinsky and his crew are true value-creation specialists with deep business data.

Because of this, buyers are more likely to discover a number of hidden gems in RA’s fairness portfolio. Be mindful, nevertheless, {that a} comparatively excessive familiarity and expertise should be possessed by retail buyers too earlier than investing within the dangerous biotech business.

Extra Sources

See the articles beneath for evaluation on different main funding corporations/asset managers:

If you’re curious about discovering extra high-quality dividend development shares appropriate for long-term funding, the next Certain Dividend databases can be helpful:

The key home inventory market indices are one other stable useful resource for locating funding concepts. Certain Dividend compiles the next inventory market databases and updates them month-to-month: